Candel Therapeutics, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.22 | $-0.35 | -59.1% | Miss |
| Q12026 FY2026 | $-0.22 | $-0.14 | +36.4% | Beat |
| Q42025 FY2025 | $-0.24 | $-0.54 | -125.0% | Miss |
Back to CADL overview · CADL holders · CADL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.